Abstract: Processes for the production of hydrocarbons from a renewable feedstock in which the renewable feedstock is partially hydrogenated prior to being deoxygenated. The partially hydrogenation utilizes a lower pressure, lower purity or both hydrogen gas compared to the deoxygenation. The partially hydrogenated product may be stored in containers and transported to be deoxygenated. Prior to partially hydrogenation, the feedstock may be pretreated. After deoxygenation an isomerization zone may be used to increase the cold flow properties for a diesel fuel.

Abstract: Apparatuses, systems and methods for separating heavy hydrocarbons from a solvent stream are disclosed. The heavy hydrocarbons and solvent can be recovered and processed further.

Abstract: A system of reforming reactors comprises a plurality of reactors coupled by flow lines, a feed header coupled to the plurality of reactors by a plurality of feed lines, an effluent header coupled to the plurality of reactors by a plurality of effluent lines, and a plurality of valves disposed in the flow lines, the feed lines, and the effluent lines. Each reactor comprises a reforming catalyst, and the plurality of valves is configured to dynamically connect the plurality of reactors to create a first serial flow path and reconnect the plurality of reactors to create a second serial flow path through the plurality of reactors. A first reactor of the plurality of reactors is adjacent to a second reactor of the plurality of reactors in the first serial flow path, and the first reactor is not adjacent to the second reactor in the second serial flow path.

Abstract: The process and apparatus of the present invention selectively hydrogenates a heavier olefinic naphtha stream in an upstream catalyst bed and the hydrogenated effluent and a lighter olefinic naphtha stream in a downstream catalyst bed. The heavier di-alkenes are less re-active and are contacted with more hydrogenation catalyst than the lighter di-alkenes which are more re-active.

Abstract: A method is provided for removing tar from a gas by contacting a first gas containing tar with a second gas containing oxygen for time period sufficient to effect oxidation of at least a portion of the tar in the first gas, thus producing an oxidized product gas that contains less tar than the first gas. The method can also include heating a fluidized particulate material in a combustor, introducing the heated fluidized particulate material from the combustor and a biomass feedstock into a gasifier, such that heat from the heated fluidized particulate material causes the gasification of at least a portion of the biomass feedstock to form a tar-containing product gas, the first gas may contain at least a portion of the tar-containing gas, and the tar-containing gas may be extracted from the gasifier prior to contacting the first gas with the second gas.

Abstract: A system for gasifying biomass is disclosed. The system comprises a water storage tank, a water pump, a heat exchanger, a plasma torch heater, a gasifier, an ash cooler, a spray tower, a dust collector, a deacidification tower, and a desiccator. The water storage tank is connected to the water inlet of the heat exchanger; the vapor outlet of the heat exchanger is connected to the vapor inlet of the plasma torch heater; the vapor outlet of the plasma torch heater is connected to the vapor nozzle of the gasifier; the ash outlet of the gasifier is connected to the ash inlet of the ash cooler; the gas outlet of the gasifier is connected to the gas inlet of the spray tower; and the gas outlet of the spray tower is connected to the gas inlet of the heat exchanger.

Abstract: A formulation and methods for making high energy organic fuels that incorporate suspended metal particles with metal particle sized ranging from 33 nm to 5 micron. The hybrid organic fuels contain superior density and/or energy content to conventional liquid organic fuels. These hybrid organic fuels used in combination with metal particle afford fuels with 5 to 80% more net heat of combustion (based on volume). These fuels should extend the distant range for jets, liquid rocket engines, SCRAM jet engines, and improve energy content in fuel-air explosive applications such as fuel-air explosives and in the Multi-Effects Weapons System (MEWS) where the fuel is used both for propulsion and explosive effects.

Abstract: Gasoline fuel and method of making and using it. The fuel comprises from 5 to 20 vol.-% paraffinic hydrocarbons originating from biological oils, fats, or derivatives or combinations thereof. Further, it comprises oxygenates, such as ethanol present in a concentration of about 5 to 15 vol.-%; or iso-butanol present in a concentration of 5 to 20 vol.-%, preferably about 10 to 17 vol.-%; or ETBE present in a concentration of 7 to 25 vol.-%, preferably about 15 to 22 vol.-%. The bioenergy content of the gasoline is at least 14 Energy equivalent percentage (Eeqv-%) calculated based on the heating values given in the European Renewable Energy Directive 2009/28/EC. By means of the invention, fuels with a high bioenergy content are provided which can be used in conventional gasoline-fuelled automotive engines.

Abstract: The invention relates to a coating comprising at least one molybdenum-containing layer having molybdenum oxide, said molybdenum being essentially molybdenum monoxide. The invention further relates to a PVD process for producing the disclosed coating, in which the layer comprising the molybdenum monoxide is produced using arc evaporation. The invention also relates to a component that has said coating.

Abstract: A composition that includes one or more compounds represented by the formula R1—O—R2 wherein R1 is a substituted or unsubstituted aryl or polyaryl group having from about 4 to about 40 carbon atoms, and R2 is a substituted or unsubstituted, linear or branched, alkyl group having from about 4 to about 40 carbon atoms. The composition has a viscosity (Kv100) from about 1 to about 10 cSt at 100° C. as determined by ASTM D-445, a viscosity index (VI) from about ?100 to about 300 as determined by ASTM D-2270, and a Noack volatility of no greater than 50 percent as determined by ASTM D-5800. The disclosure also relates to a process for producing the composition, a lubricating oil base stock and lubricating oil containing the composition, and a method of reducing boundary friction and improving dispersancy of polar additives of a lubricating oil by using as the lubricating oil a formulated oil containing the composition.

Abstract: Provided are compositions and their use as dispersant and/or detergent additives for lubricants. The compositions comprise an amine alkoxylate of the formula I: (I) wherein R1-R7, R1?-R7; x, x?, A, A? and A? are as defined herein.

Abstract: This invention involves a process for reducing friction in ethanol during its transport through pipelines. This process involves combining ethanol with a polymer-based composition, characterized in that the polymer is obtained from at least 50 mol % of at least one monomer selected from the group comprising N-substituted acrylamides, N-substituted methacrylamides, N,N-substituted acrylamides, N,N-substituted methacrylamides, substituted acrylates and substituted methacrylates.

Abstract: This disclosure provides low viscosity, low volatility alkylated siloxane compounds and alkylated alkoxy silane compounds. This disclosure also provides processes for producing the alkylated siloxane compounds and alkylated alkoxy silane compounds, and lubricating oil basestocks and lubricating oils containing one or more of the alkylated siloxane compounds or one or more of the alkylated alkoxy silane compounds. This disclosure further provides a method for improving one or more of solubility and dispersancy of polar additives and/or sludge in a lubricating oil by using as the lubricating oil a formulated oil containing one or more of the alkylated siloxane compounds or one or more of the alkylated alkoxy silane compounds.

Abstract: The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities' options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles.

Abstract: A cleaner and method for maintaining bearings, bushings, linkage pins and chains used in various types of machinery, including industrial machinery is disclosed. The cleaner is effective to rejuvenate spent grease and includes a polar fraction, a miscible non-polar fraction, and a non-ionic surface activating agent.

Abstract: A container assembly (10) for retaining a liquid (16) during aging of the liquid (16) comprises a container (12) and an oxygenator (230). The container (12) includes a container body (14) that defines a chamber (14A) that receives and retains the liquid (16). The oxygenator (230) is positioned substantially within the chamber (14A). The oxygenator (230) includes a fluid source (662), one or more diffusers (672), and a valve (670). The one or more diffusers (672) are in fluid communication with the fluid source (662). The valve (670) selectively controls the introduction of a fluid from the fluid source (662) into the liquid (16) through the one or more diffusers (672). The container assembly (10) further comprises an insert retainer assembly (338) and one or more flavor inserts (440) that are received and retained by the insert retainer assembly (338). The container (12) further includes a container aperture (20) that extends through the container body (14).

Abstract: There is provided a new material that can form a finer pattern and can be applied to adsorption/adhesion control of various cell species, proteins, viruses, and the like without the limitation of the light source. A light-degradable material comprising: a moiety that is capable of bonding to a surface of a substrate through a siloxane bond; and a structural unit of Formula (2-a) and/or Formula (2-b): (where R2 to R4 are saturated linear alkyl groups; X is a hydrogen atom or an alkyl group; Z is a carbanion or a sulfo anion; Q is an ester bond group, a phosphodiester bond group, an amido bond group, an alkylene group, or an phenylene group or a combination of these divalent groups; m1 is an integer of 1 to 200, and n is an integer of 1 to 10).

Abstract: The method comprises an automated removal of cells and/or cell colonies from a cell culture whilst executing a first detection step for selecting cells and/or cell colonies with reference to corporeal and/or physical parameters and detecting position data and storing the detected position data of the selected cells and/or cell colonies in a position database. In order to be able to select special cells and/or cell colonies having special properties from the detected cells and/or cell colonies, at least one second detection step for detecting at least one further parameter of the cells and/or cell colonies is then executed, comparative data from the data of the first and second detection step are created, cells and/or cell colonies are selected with reference to the comparative data and the position data from the position database are transferred to a harvesting unit.

Abstract: A system for digesting biodigestible feed that preferably includes the steps of comminuting the feed, introducing feed, an oxygen-containing gas, an accelerant, and bacteria into a digestion zone, the bacteria being suitable for digesting the feed under aerobic, anaerobic, and anoxic conditions. The contents of the digestion zone can be changed from aerobic operation to either anoxic or anaerobic operation, or vice versa, without changing the bacteria in the digestion zone.

Abstract: Acoustic perfusion devices for separating biological cells from other material in a fluid medium are disclosed. The devices include an inlet port, an outlet port, and a collection port that are connected to an acoustic chamber. An ultrasonic transducer creates an acoustic standing wave in the acoustic chamber that permits a continuous flow of fluid to be recovered through the collection port while keeping the biological cells within the acoustic chamber to be returned to the bioreactor from which the fluid medium is being drawn.

Abstract: A method for treating silage to enhance the aerobic stability by increasing the fermentation and stabilization of silage by inhibiting growth of microorganisms selected from yeasts, molds and spore-forming bacteria and permitting earlier aerobic 5 exposure is disclosed. The method comprises treating silage or feed with a composition comprising Lactobacillus buchneri strain LN7125, or Lactobacillus brevis strain LB5328, or Lactobacillus brevis strain LB7123, and mixtures or a mutant thereof which retains the silage preservative activity of LN7125, LB5328, or LB7123, or the antimicrobial components produced thereby. The strains of Lactobacillus 10 buchneri and Lactobacillus brevis disclosed in the invention have been purified and isolated and have been found to improve aerobic stability of silage allowing earlier aerobic exposure post ensiling than is presently practiced.

Abstract: This invention provides an Amycolatopsis sp. strain (zhp06), and a method of using the whole cell preparation of the strain for vanillin production. The strain was deposited in China Center for Type Culture Collection on Jul. 26, 2011 with the number of CCTCC NO: M 2011265. Under high concentrations of ferulic acid substrate, the vanillin production by this method can reach more than 10 g/L. The molar conversion rate of ferulic acid is more than 50% and the purity of vanillin is from 80% to 95%. The advantage of this invention includes: repeated use of biocatalyst cells, mild biotransformation condition, low environmental pollution, short production cycle, high product purity and simple purification procedure. It has a great potential for industrial applications.

Abstract: A method for making an at least double layered cell aggregate and/or an artificial blastocyst, and/or a further-developed blastoid termed blastoid, by forming a double layered cell aggregate from at least one trophoblast cell and at least one pluripotent and/or totipotent cell, and culturing the aggregate to obtain an artificial blastocyst having a trophectoderm-like tissue that surrounds a blastocoel and an inner cell mass-like tissue. The cell aggregate can be formed from toti- or pluripotent stem cell types, or induced pluripotent stem cell types, in combination with trophoblast stem cells. Formation of a blastoid can be achieved by culturing the cell aggregate in a medium preferably comprising one or more of a Rho/ROCK inhibitor, a Wnt pathway modulator, a PKA pathway modulator, a PKC pathway modulator, a MAPK pathway modulator, a STAT pathway modulator, an Akt pathway modulator, a Tgf pathway modulator and a Hippo pathway modulator.

Abstract: A device for performing micro-operations on a vesicular target, comprising an injection pipette (27); a barrel assembly (9); and an outer assembly (1). The injection pipette, barrel assembly, and outer assembly being designed and situated in relation to each other such that an axial vacuum passage is created between the injection pipette and the barrel assembly, and a radial vacuum passage is created between the barrel assembly and outer assembly, and such vacuum passages are isolated from each other and from atmospheric pressure (FIG. 8). The device also comprises a means of advancing and withdrawing the distal end of the barrel assembly in relation to the distal end of the outer assembly so as to create a holding well (31) and a means of advancing the pipette into, and withdrawing the pipette from, a vesicular object.

Abstract: Methods, compositions and kits for producing functional neurons, astroctyes, oligodendrocytes and progenitor cells thereof are provided. These methods, compositions and kits find use in producing neurons, astrocytes, oligodendrocytes, and progenitor cells thereof for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the CNS. Also provided are methods, compositions and kits for screening candidate agents for activity in converting cells into neuronal cells, astrocytes, oligodendrocytes, and progenitor cells thereof.

Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

Abstract: The present disclosure relates to a tissue collection apparatus. The tissue collection apparatus comprises a housing defining an inlet and an outlet, a first filter disposed within the housing, a second filter disposed within the housing, the second filter configured to isolate tissue particles of a desired size that pass through the first filter under the application of an aspiration force applied through the housing. A method of harvesting tissue is also disclosed.

Abstract: The present invention provides a method for efficiently producing cardiomyocytes from pluripotent stem cells, which method comprises the steps of dissociating embryoid bodies obtained during the production process, and allowing reaggregation of the resulting cells to allow formation of embryoid bodies.

Abstract: This document provides methods and materials involved obtaining induced pluripotent stem (iPS) cells. For example, methods and materials for increasing the efficiency for making iPS cells as well as methods and materials for selecting iPS cells are provided.

Abstract: Provided is a method by which cells deviated from the undifferentiated state, which emerge in a colony during culture of stem cells having pluripotency, can be removed. In one aspect, provided is a method for culturing stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion. In another aspect, provided is a method for removing cells deviated from the undifferentiated state, the cells being cells that have emerged or may possibly emerge during culture of stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion. In still another aspect, provided is a method for maintaining the undifferentiated state of stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion.

Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.

Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Abstract: The invention relates to an expression system comprising a prokaryotic cell which contains a polynucleotide construct that encodes a T7 RNA polymerase under the control of a T7 promoter and under the control of an inducible promoter. The invention also relates to an expression vector which contains a gene that encodes a protein to be expressed under the control of a T7 promoter, characterized in that said expression vector comprises a plasmid stabilization system.

Abstract: The present invention relates to isolated polypeptides having alpha-L-arabinofuranosidase activity and isolated nucleic acid sequences encoding the polypeptides, such that the nucleic acid is operably linked to a heteroloqous control sequence for expression. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides set forth in SEQ ID NO:2 and fragments of SEQ ID NO:2.

Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The present invention relates to a hyaluronidase from S. koganeiensis, applications thereof and a method for the production thereof.

Abstract: A variant polypeptide having chymosin activity, wherein the variant has an amino acid sequence which, when aligned with the chymosin comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue corresponding to any of amino acids 2, 22, 40, 48, 50, 51, 53, 61, 62, 76, 88, 98, 99, 109, 112, 117, 125, 126, 135, 144, 160, 161, 163, 187, 189, 194, 200, 201, 202, 203, 221, 223, 240, 242, 244, 254, 267, 271, 273, 278, 280, 284, 289, 292, 294 or 295 said positions being defined with reference to SEQ ID NO: 2 and wherein the variant has one or more altered properties as compared with a reference polypeptide having chymosin activity. Such a variant polypeptide may be used in the preparation of a cheese.

Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.

Abstract: The present invention relates to an acyl-CoA synthetase homolog protein from microorganisms of the genus Mortierella, a polynucleotide encoding the protein, and so on. The invention provides polynucleotides comprising an acyl-CoA synthetase homolog protein gene from, e.g., Mortierella alpina, expression vectors comprising these polynucleotides and transformants thereof, a method for producing lipids or fatty acids using the transformants, food products containing the lipids or fatty acids produced by the method, etc.

Abstract: Provided herein are methods and compositions for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels.

Abstract: The present invention relates to fluidic devices for preparing, processing, storing, preserving, and/or analyzing samples. In particular, the devices and related systems and methods allow for preparing and/or analyzing samples (e.g., biospecimen samples) by using one or more of capture regions and/or automated analysis.

Abstract: The invention refers to a library of bidirectional expression cassettes or expression vectors comprising a repertoire of bidirectional promoter sequences, each expression cassette comprising a promoter sequence operably linked to a first gene in one direction, and operably linked to an oppositely oriented second gene in the other direction which is different from the first gene, and bidirectional Pichia pastoris or CHO cells promoter sequences. The invention further refers to a method of screening or selecting a bidirectional promoter suitable for expressing at least two GOI in a host cell and a kit comprising a) an expression cassette consisting of the first and second genes and a stuffer sequence separating them, which stuffer sequence comprises a recognition site for a type IIS restriction enzyme at both ends; b) the type IIS restriction enzyme; c) and a repertoire of promoter, preferably a promoter library including bidirectional promoters.

Abstract: The invention relates to the treatment and prevention of cancers, including blood-based cancers and breast cancers, by administering agents that inhibit the activity of microRNAs, including miR-22. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oligonucleotides, including locked nucleic acids (LNAs).

Abstract: A method of treating traumatic brain injury (TBI) and other neurological disorders is presented herein. Both conditioned media (CM) containing long non-coding RNAs such as NEAT1 (nuclear enriched abundant transcript 1) and MALAT1 (metastasis associated lung adenocarcinoma transcript 1) as well as human adipose-derived stem cells (hADSCs) themselves (Tx), when administered at least 3 hours post injury, were found to significantly ameliorate motor and cognitive functions in young, but not aged, mice undergoing TBI. Significant reduction in cortical damage and hippocampal cell loss was observed in both Tx and CM groups in young rats, whereas less neuroprotection was detected in the aged rats and mainly in the Tx group but not the CM group, which may in part result from decreased homing of the cells to the spleen.

Abstract: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3??P5? phosphoramidate (NP) and ribo-N3??P5? thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.

Abstract: Novel processes and compositions are described which use viral capsid proteins resistant to hydrolases to prepare virus-like particles to enclose and subsequently isolate and purify target cargo molecules of interest including nucleic acids such as siRNAs and shRNAs, miRNAs, messenger RNAs, small peptides and bioactive molecules.

Abstract: Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising down-regulating the TLR2 gene or both the TLR2 gene and TLR4 gene.

Abstract: The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor C 40 (RFC40). Methods and assays for evaluating breast cancer are provided. The disclosure also relates to inhibition or modulation of RFC40 in treatment or alleviation of cancer, including breast cancer. RFC40 inhibitors, including siRNAs, miRNAs, and shRNAs, which specifically affect cancer cells, particularly breast cancer cells, are provided.